Extensive Clinical Experience
In addition to global commercial sales, NanoPass’ NanoPass’s MicronJetTM technology has already been used to administer over 27,000 injections to approximately 5,700 patients in more than 55 clinical trials, some still ongoing. The studies, conducted on subjects ranging in age from 6-week-old infants to 95 years in North America, Europe, Israel, Hong Kong, Brazil, Bangladesh and Japan, represent one of the industry’s most comprehensive database on intradermal delivery.
Intradermal vaccine delivery has been repeatedly shown to allow significant dose sparing when compared to conventional administration methods such as intramuscular and subcutaneous administration. The dermis and epidermis of the human skin are rich in antigen-presenting cells, such as Langerhans cells and dendritic cells, which play a critical role in the induction of immune responses. Injection of vaccines into these layers delivers antigens closer to these cells thus smaller doses of antigen might induce an equivalent immune response to the standard dose*.
*Darin Zehrung et al. Intradermal delivery for vaccine dose sparing: Overview of current issues. Vaccine 31 (2013) 3392– 3395
MicronJetTM has demonstrated significant dose sparing with various vaccines with down to 4% of the original dose1-8,10. It is also the first intradermal device to demonstrate dose sparing in pandemic flu4.
MicronJetTM has demonstrated a superior immune response to full dose Fluzone® intramuscular5 and improved immunogenicity to full-dose ZostaVax® and overall trend for superiority with lower doses8.